Janssen Biotech Company Profile
✉ Email this page to a colleague
What is the competitive landscape for JANSSEN BIOTECH, and when can generic versions of JANSSEN BIOTECH drugs launch?
JANSSEN BIOTECH has five approved drugs.
There are thirty-five US patents protecting JANSSEN BIOTECH drugs.
There are eight hundred and thirty-four patent family members on JANSSEN BIOTECH drugs in sixty-one countries and seventy-three supplementary protection certificates in twenty countries.
Summary for Janssen Biotech
International Patents: | 834 |
US Patents: | 35 |
Tradenames: | 5 |
Ingredients: | 5 |
NDAs: | 5 |
Patent Litigation for Janssen Biotech: | See patent lawsuits for Janssen Biotech |
Drugs and US Patents for Janssen Biotech
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Janssen Biotech | AKEEGA | abiraterone acetate; niraparib tosylate | TABLET;ORAL | 216793-001 | Aug 11, 2023 | RX | Yes | No | 11,091,459 | ⤷ Subscribe | Y | Y | ⤷ Subscribe | ||
Janssen Biotech | BALVERSA | erdafitinib | TABLET;ORAL | 212018-003 | Apr 12, 2019 | RX | Yes | Yes | 9,902,714 | ⤷ Subscribe | Y | ⤷ Subscribe | |||
Janssen Biotech | BALVERSA | erdafitinib | TABLET;ORAL | 212018-001 | Apr 12, 2019 | RX | Yes | No | 9,902,714 | ⤷ Subscribe | Y | ⤷ Subscribe | |||
Janssen Biotech | BALVERSA | erdafitinib | TABLET;ORAL | 212018-002 | Apr 12, 2019 | RX | Yes | No | 11,077,106 | ⤷ Subscribe | ⤷ Subscribe | ||||
Janssen Biotech | BALVERSA | erdafitinib | TABLET;ORAL | 212018-001 | Apr 12, 2019 | RX | Yes | No | 10,898,482 | ⤷ Subscribe | Y | ⤷ Subscribe | |||
Janssen Biotech | LAZCLUZE | lazertinib mesylate | TABLET;ORAL | 219008-001 | Aug 19, 2024 | RX | Yes | No | 9,593,098 | ⤷ Subscribe | Y | Y | ⤷ Subscribe | ||
Janssen Biotech | LAZCLUZE | lazertinib mesylate | TABLET;ORAL | 219008-001 | Aug 19, 2024 | RX | Yes | No | 11,453,656 | ⤷ Subscribe | Y | Y | ⤷ Subscribe | ||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Janssen Biotech
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Janssen Biotech | ZYTIGA | abiraterone acetate | TABLET;ORAL | 202379-001 | Apr 28, 2011 | 5,604,213 | ⤷ Subscribe |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for JANSSEN BIOTECH drugs
Drugname | Dosage | Strength | Tradename | Submissiondate |
---|---|---|---|---|
➤ Subscribe | Tablets | 500 mg | ➤ Subscribe | 2017-08-23 |
➤ Subscribe | Tablets | 250 mg | ➤ Subscribe | 2015-04-28 |
International Patents for Janssen Biotech Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
Australia | 2004294790 | ⤷ Subscribe |
Austria | 508118 | ⤷ Subscribe |
Canada | 3059543 | ⤷ Subscribe |
Eurasian Patent Organization | 032145 | ⤷ Subscribe |
Eurasian Patent Organization | 201992501 | ⤷ Subscribe |
Mexico | 2021004110 | ⤷ Subscribe |
Portugal | 3533792 | ⤷ Subscribe |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Janssen Biotech Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
3533792 | 122021000067 | Germany | ⤷ Subscribe | PRODUCT NAME: APALUTAMID; REGISTRATION NO/DATE: EU/1/18/1342 20190114 |
1633724 | 13/2015 | Austria | ⤷ Subscribe | PRODUCT NAME: OLAPARIB UND SALZE UND SOLVATE DAVON; REGISTRATION NO/DATE: EU/1/14/959 20141216 |
2240466 | 132018000000301 | Italy | ⤷ Subscribe | PRODUCT NAME: NIRAPARIB TOSILATO O UN SUO IDRATO, IN PARTICOLARE IL TOSILATO MONOIDRATO(ZEJULA); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/17/1235, 20171120 |
2368550 | C 2019 029 | Romania | ⤷ Subscribe | PRODUCT NAME: APALUTAMIDA SAU O SARE ACCEPTABILA FARMACEUTIC A ACESTEIA; NATIONAL AUTHORISATION NUMBER: EU/1/18/1342; DATE OF NATIONAL AUTHORISATION: 20190114; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/18/1342; DATE OF FIRST AUTHORISATION IN EEA: 20190114 |
2109608 | C201830023 | Spain | ⤷ Subscribe | PRODUCT NAME: NIRAPARIB; NATIONAL AUTHORISATION NUMBER: EU/1/17/1235; DATE OF AUTHORISATION: 20171116; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/17/1235; DATE OF FIRST AUTHORISATION IN EEA: 20171116 |
2368550 | CA 2019 00029 | Denmark | ⤷ Subscribe | PRODUCT NAME: APALUTAMID ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF; REG. NO/DATE: EU/1/18/1342 20190116 |
2368550 | CR 2019 00029 | Denmark | ⤷ Subscribe | PRODUCT NAME: APALUTAMID ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF; REG. NO/DATE: EU/1/18/1342 20190116 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.